China, Sept. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An exploratory study on the safety and efficacy of 177Lu-FAP-2286 versus 225Ac-FAP-2286 therapy for FAP-positive advanced pancreatic ductal adenocarcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600131931
Registration Time: 2026/09/08
Type: Interventional study
Primary Sponsor: The affiliated hospital of southwest medical university
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342028
Published by HT Digital Content Services with permission from Health Daily Digest....